Pacira BioSciences announced that the Centers for Medicare and Medicaid Services has established a permanent product-specific Healthcare Common Procedure Coding System J-code for EXPAREL. The new J-code for EXPAREL, J0666, becomes effective January 1, 2025, and will supersede the current C-code, which has been in place since 2019. In addition to the separate CMS reimbursement EXPAREL will receive in outpatient settings with the implementation of NOPAIN in January 2025, this new J-code will also provide reimbursement when EXPAREL is used in the office setting and for office-based surgeries.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- Pacira completes acquisition of pharmacy business in Atlantic Canada
- Pacira Pharmaceuticals Announces CFO Transition and Interim Replacement
- Pacira presents 104-week safety, efficacy data following PCRX-201 administration
- DOMA Perpetual urges Pacira to accelerate, increase its stock repurchases
- Pacira price target raised to $18 from $15 at Jefferies